Fruquintinib Emerging Drug Insight

“Fruquintinib Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about Fruquintinib for Metastatic Colorectal Cancer (mCRC) in the 7MM. A detailed picture of the Fruquintinib for Metastatic Colorectal Cancer in the 7MM, i.e., United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019–2032 is provided in this report along with a detailed description of the Fruquintinib for Metastatic Colorectal Cancer. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Fruquintinib market forecast, analysis for Metastatic Colorectal Cancer in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Metastatic Colorectal Cancer.

Drug Summary

Fruquintinib is a highly selective and potent oral inhibitor of vascular endothelial growth factor receptor (VEGFR) 1/2/3. VEGFR inhibitors play a pivotal role in blocking tumor angiogenesis. The drug is designed to improve kinase selectivity to minimize off-target toxicities, improve tolerability, and provide more consistent target coverage. The generally good tolerability observed in patients to date, along with fruquintinib’s low potential for drug-drug interaction based on preclinical assessment, suggests that it may also be highly suitable for combinations with other anti-cancer therapies.

In 2018, Hutchison Medipharma announced that the National Medical Products Administration of China had granted approval to fruquintinib for the treatment of metastatic colorectal cancer (""CRC"") patients who have failed at least two prior systemic antineoplastic therapies, including fluoropyrimidine, oxaliplatin, and irinotecan, with or without prior use of anti-vascular endothelial growth factor (""VEGF"") or anti-epidermal growth factor receptor (""EGFR"") therapies. In China, fruquintinib is marketed under the brand name of Elunate. The approval of fruquintinib was based on the FRESCO trial (NCT02314819) conducted in China, and in the FRESCO trial, fruquintinib was shown to provide a statistically significant and clinically meaningful improvement in overall survival (""OS"") versus placebo, with a median OS of 9.3 vs. 6.6 months, respectively, and a manageable safety profile. In addition to the significant efficacy, fruquintinib’s good kinase selectivity has been shown to limit off-target toxicity.

The company has initiated a FRESCO-2 Phase III trial (NCT04322539), which is being conducted to evaluate the efficacy and safety of fruquintinib in a patient population with refractory mCRC (3L+) and is being conducted in 7MM.

The FDA granted the drug fast-track designation in 2020, and Hutchmed began a rolling submission of a new drug application, which is planned to be completed in the first half of 2023.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the Fruquintinib description, mechanism of action, dosage and administration, research and development activities in Metastatic Colorectal Cancer.
• Elaborated details on Fruquintinib regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Fruquintinib research and development activity in Metastatic Colorectal Cancer in detail across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around Fruquintinib.
• The report contains forecasted sales of Fruquintinib for Metastatic Colorectal Cancer till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Metastatic Colorectal Cancer.
• The report also features the SWOT analysis with analyst views for Fruquintinib in Metastatic Colorectal Cancer.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Fruquintinib Analytical Perspective by DelveInsight

In-depth Fruquintinib Market Assessment

This report provides a detailed market assessment of Fruquintinib in Metastatic Colorectal Cancer in the 7MM, i.e., United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

Fruquintinib Clinical Assessment

The report provides the clinical trials information of Fruquintinib in Metastatic Colorectal Cancer covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for Metastatic Colorectal Cancer is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Fruquintinib dominance.
• Other emerging products for Metastatic Colorectal Cancer are expected to give tough market competition to Fruquintinib and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Fruquintinib in Metastatic Colorectal Cancer.
• Our in-depth analysis of the forecasted sales data of Fruquintinib from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Fruquintinib in Metastatic Colorectal Cancer.

Key Questions

• What is the product type, route of administration and mechanism of action of Fruquintinib?
• What is the clinical trial status of the study related to Fruquintinib in Metastatic Colorectal Cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Fruquintinib development?
• What are the key designations that have been granted to Fruquintinib for Metastatic Colorectal Cancer?
• What is the forecasted market scenario of Fruquintinib for Metastatic Colorectal Cancer?
• What are the forecasted sales of Fruquintinib in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available in Metastatic Colorectal Cancer and how are they giving competition to Fruquintinib for Metastatic Colorectal Cancer?
• Which are the late-stage emerging therapies under development for the treatment of Metastatic Colorectal Cancer?